Safety of an intravenous formulation of lamotrigine.

导出 OA

翻译打印收藏纠错

作者： Jeannine M,Conway ^[1] ; Angela K,Birnbaum ^[2] ; Ilo E,Leppik ^[3] ; Page B,Pennell ^[4] ; James R,White ^[5] ; John O,Rarick ^[1] ; Rory P,Remmel ^[6]

作者单位： Experimental and Clinical Pharmacology, 308 Harvard Street SE, Minneapolis, MN 55455, United States. ^[1] Experimental and Clinical Pharmacology, 308 Harvard Street SE, Minneapolis, MN 55455, United States. Electronic address: birnb002@umn.edu. ^[2] Experimental and Clinical Pharmacology, 308 Harvard Street SE, Minneapolis, MN 55455, United States; Department of Neurology, 420 Delaware St. SE, University of Minnesota, Minneapolis, MN 55455, United States; MINCEP Epilepsy Care, 5775 Wayzata Boulevard, Minneapolis, MN 55416, United States. ^[3] Department of Neurology and Division of Women's Health at Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, United States. ^[4] MINCEP Epilepsy Care, 5775 Wayzata Boulevard, Minneapolis, MN 55416, United States. ^[5] Department of Medicinal Chemistry, 308 Harvard Street SE, University of Minnesota, Minneapolis 55455, MN, United States. ^[6]

关键词 Cyclodextrin Epilepsy Intravenous Lamotrigine Safety